Lava Therapeutics B.V. (id:8429 LVTX)
3.00 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/24/2024 11:53:46 AM)
Exchange open, closes in 4 hours 6 minutes
About Lava Therapeutics B.V.
Market Capitalization 31.82M
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
| Headquarters (address) |
Yalelaan 62 Utrecht 3584 CM Netherlands |
| Phone | 31 85 016 3100 |
| Website | https://www.lavatherapeutics.com |
| Employees | 37 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | LVTX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.00 - 6.47 |
| Market Capitalization | 31.82M |
| P/E trailing | 3.00 |
| P/E forward | 3.00 |
| Price/Sale | 4.30 |
| Price/Book | 3.00 |
| Beta | 3.00 |
| EPS | -1.01 |
| EPS Netherlands (ID:23, base:88) | 1.55 |